Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/1999
06/22/1999US5914326 Coadministering to the patient daily effective weight and fat loss promoting amounts of hydroxycitrate, carnitine, chromic tripicolinate and metformin or biotin which promotes intramitochondrial generation of oxaloacetate
06/22/1999US5914325 Steroids with radical-attracting aromatic substituents, process for the production thereof and pharmaceutical compounds containing the said substances
06/22/1999US5914324 6-Hydroxy and 6-oxo-androstane derivatives active on the cardiovascular system and pharmaceutical compositions containing same
06/22/1999US5914323 Treating hypercalcemia of malignancy, metastatic bone disease and/or metabolic bone disease by administering an isotonic aqueous alendronate solution with a buffer to maintain the ph in the range 4 to 8 to prevent precipitation
06/22/1999US5914322 Treatment of disease and conditions
06/22/1999US5914321 Antitumoral method by administration of partricin derivatives
06/22/1999US5914314 Hyaluronic acid and its nontoxic salts facilitate penetration of immunosuppressent through underperfused or pathological tissue, including scar tissue
06/22/1999US5914242 Administering fostriecin or analog to patient after onset of cardiac ischemia
06/22/1999US5914233 Screening assay for the identification of agents which alter expression of PTH-rP
06/22/1999US5914134 Process for the pulsatile delivery of diltiazem HCL and product produced thereby
06/22/1999US5914132 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
06/22/1999US5914131 Hydromorphone therapy
06/22/1999US5914126 Methods to deliver macromolecules to hair follicles
06/22/1999US5914122 Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
06/22/1999US5914118 Multi-layered drug containing film preparation having powder adhesive thereon
06/22/1999US5914099 Prevention of tooth loss by the administration of alendronate or its salts
06/22/1999US5914095 Polychelants containg amide bonds
06/22/1999CA2256252A1 Chrolactomycin compound
06/22/1999CA2176370C The use of steroids having a phenolic a-ring structure for prophylaxis and therapy of radical-mediated cellular trauma
06/22/1999CA2169066C Phenoxyphenyl cyclopentenyl hydroxyureas
06/22/1999CA2151674C Methods of administering crf antagonists
06/22/1999CA2147893C Enantiomerically pure .beta.-d-dioxolane nucleosides with selective anti-hepatitis .beta. virus activity
06/22/1999CA2114970C Derivatives of amino-ascorbic, processes for their preparation and use
06/22/1999CA2019614C Antihypertensives and food and drinks
06/22/1999CA1340608C Alkoxy-4(1h)-pyridone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
06/22/1999CA1340604C Process for the preparation of 7-[2-(2-aminothiazol-4-y1)-2-hydroxyiminoacetamido]-3-cephem compounds
06/22/1999CA1340603C Tri-aza macrocycles and metal complexes thereof
06/20/1999CA2255143A1 Binding partners for inhibitors of cyclin-dependent kinases and their use for searching for inhibitors and for the diagnosis or therapy of a disease
06/20/1999CA2255141A1 Nucleic acid constructs for gene therapy whose activity is affected by inhibitors of cyclin-dependent kinases
06/19/1999CA2256303A1 The use of mmp inhibitors for the treatment of ocular angiogenesis
06/17/1999WO1999030157A2 Neuropilins in methods for diagnosis and prognosis of cancer
06/17/1999WO1999029878A2 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
06/17/1999WO1999029861A1 Peptide antagonists of vascular endothelial growth factor
06/17/1999WO1999029860A1 Cadherin-like polypeptides, methods and compositions related thereto
06/17/1999WO1999029856A1 Restin and methods of use thereof
06/17/1999WO1999029855A1 Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
06/17/1999WO1999029853A1 Cadherin-like polypeptides, methods and compositions related thereto
06/17/1999WO1999029852A1 High-affinity tryptophan transporter
06/17/1999WO1999029842A1 Nucleic acid mediated rna tagging and rna revision
06/17/1999WO1999029839A1 Grafted copolymers as gene carriers
06/17/1999WO1999029735A1 Non-aqueous, heterogeneous polymerization process and reaction product obtained thereby
06/17/1999WO1999029734A1 Dextran derivatives, preparation method and applications as medicine with specific biological action
06/17/1999WO1999029731A1 Use of substances with immunomodulating activity for the treatment of amyotrophic lateral sclerosis
06/17/1999WO1999029700A2 Cyclohexadiene-derivatives as pesticides
06/17/1999WO1999029697A1 Pharmaceuticals
06/17/1999WO1999029696A1 Piperidine derivatives
06/17/1999WO1999029695A1 Novel compounds
06/17/1999WO1999029694A1 Purine compounds having pde iv inhibitory activity and methods of synthesis
06/17/1999WO1999029693A1 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
06/17/1999WO1999029688A1 S-oxide and s,s-dioxide tetrahydrothiopyran phenyloxazolidinones
06/17/1999WO1999029687A1 (benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
06/17/1999WO1999029686A1 Novel compounds
06/17/1999WO1999029685A1 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2-[(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt
06/17/1999WO1999029674A1 Retinoic acid mimetic anilides
06/17/1999WO1999029673A1 SELECTIVE β3 ADRENERGIC AGONISTS
06/17/1999WO1999029672A1 SELECTIVE β3 ADRENERGIC AGONISTS
06/17/1999WO1999029669A1 Urethanes derived from azacycloalkanes, thio and dithio analogues, production and use thereof as 2,3 epoxysqualene lanesterol cyclase inhibitors
06/17/1999WO1999029667A1 Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
06/17/1999WO1999029662A2 Urethanes, thio and dithio analogues, the salts thereof, medicaments containing said compounds, use and method for the production thereof
06/17/1999WO1999029661A1 Adamantane derivatives
06/17/1999WO1999029660A1 Adamantane derivatives
06/17/1999WO1999029657A1 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
06/17/1999WO1999029655A1 Novel antiarrhythmic compounds
06/17/1999WO1999029640A2 Compositions and methods for modulating the activity of fibroblast growth factor
06/17/1999WO1999029350A1 Compositions and methods for treatment of hepatitis c virus-associated diseases
06/17/1999WO1999029347A1 Pharmaceutical combination with analgesic activity, containing an adenosinergic agonist and a compound selected from opiates, benzodiazepines and nmda antagonists
06/17/1999WO1999029346A1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma
06/17/1999WO1999029339A2 Prevention and/or treatment of allergic conditions
06/17/1999WO1999029331A1 The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents
06/17/1999WO1999029328A1 Modified polysaccharides exhibiting altered biological recognition
06/17/1999WO1999029327A1 Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
06/17/1999WO1999029326A1 Creams containing vitamin d3 derivatives
06/17/1999WO1999029324A1 Preventives/remedies for diabetes
06/17/1999WO1999029323A1 Use of 5ht1a receptor antagonists for preventing and/or treating temporal lobe epilepsy
06/17/1999WO1999029322A1 Magnesium quinolone antibiotics
06/17/1999WO1999029321A1 Inhibition of membrane-associated viral replication
06/17/1999WO1999029320A1 Novel administration form comprising an acid-labile active compound
06/17/1999WO1999029319A2 Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds
06/17/1999WO1999029318A1 Antiviral compounds
06/17/1999WO1999029317A1 Methods and compositions for treating diabetes
06/17/1999WO1999029316A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
06/17/1999WO1999029315A1 Taurine derivatives usable in the treatment of ophthalmic disorders
06/17/1999WO1999029314A1 Novel salts of metformin and method
06/17/1999WO1999029313A1 Method of increasing the production and improving the quality of semen
06/17/1999WO1999029312A1 Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds
06/17/1999WO1999029310A2 Regulation of t cell-mediated immunity by tryptophan and its analogs
06/17/1999WO1999029309A2 2,2'-bi-1h-pyrrole derivatives useful in the treatment of leukemia brought on by htlv-i
06/17/1999WO1999029308A2 Method for combating obesity
06/17/1999WO1999029305A1 Sustained release formulation containing three different types of polymers and tablet formed therefrom
06/17/1999WO1999029303A1 Biodegradable mixed polymeric micelles for gene delivery
06/17/1999WO1999029300A1 Self-emulsifying fenofibrate formulations
06/17/1999WO1999029299A1 Novel suppository form comprising an acid-labile active compound
06/17/1999WO1999029296A1 Pharmaceutical aerosol compositions
06/17/1999WO1999029294A1 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners
06/17/1999WO1999029293A1 Compositions comprising a combination of a free sphingoid base and a ceramide and uses thereof
06/17/1999WO1999029288A1 Reduction of hair growth
06/17/1999WO1999029173A1 Composition useful for providing one-step surgical preparation and drape
06/17/1999WO1999017742A3 Taste masked formulations
06/17/1999WO1999016442A3 Sustained release tablet formulation to treat parkinson disease
06/17/1999WO1999016426A3 Multilamellar coalescence vesicles (mlcv) containing biologically active compounds
1 ... 6485 6486 6487 6488 6489 6490 6491 6492 6493 6494 6495 6496 6497 6498 6499 6500 6501 6502 6503 6504 6505 ... 7860